|
3 Companies |
|
0 Products |
|
0 Products |
|
1 Mechanism of Action |
|
0 Trials |
|
43 News |
|
- | Sm-TSP-2/Alhydrogel vaccine / Baylor College of Medicine, National Institutes of Health
Trial completion: A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel (clinicaltrials.gov) - Jun 26, 2017
P1, N=72, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed
- Sm-TSP-2/Alhydrogel vaccine / Baylor College of Medicine, National Institutes of Health
Enrollment closed, Trial primary completion date: A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel (clinicaltrials.gov) - Jan 23, 2017
P1, N=72, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Feb 2017
- | praziquantel / Generic mfg.
Trial completion: Bilhvax3: Efficacy of Bilhvax in Association With Praziquantel for Prevention of Clinical Recurrences of Schistosoma Haematobium (clinicaltrials.gov) - Nov 8, 2016
P3, N=250, Completed, Sponsor: Institut National de la Sant
Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Feb 2017 Recruiting --> Completed
- Trial completion, Enrollment change: NIDIAGDigest: Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders (clinicaltrials.gov) - Oct 25, 2016
P=N/A, N=2800, Completed, Sponsor: Swiss Tropical & Public Health Institute
Recruiting --> Completed Active, not recruiting --> Completed | N=4000 --> 2800
- Trial completion: Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis (clinicaltrials.gov) - Aug 10, 2016
P1, N=20, Completed, Sponsor: Oswaldo Cruz Foundation
Active, not recruiting --> Completed | N=4000 --> 2800 Active, not recruiting --> Completed
- Enrollment closed, Trial primary completion date: NIDIAGDigest: Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders (clinicaltrials.gov) - Jan 26, 2016
P=N/A, N=4000, Active, not recruiting, Sponsor: Swiss Tropical & Public Health Institute
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Mar 2016
- Trial completion, Enrollment change: Health Benefits of Repeated Treatment in Pediatric Schistosomiasis (clinicaltrials.gov) - Jun 6, 2015
P=N/A, N=360, Completed, Sponsor: University of Edinburgh
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Mar 2016 Active, not recruiting --> Completed | N=700 --> 360
- Sm-TSP-2/Alhydrogel vaccine / Baylor College of Medicine, National Institutes of Health
Enrollment open: A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel (clinicaltrials.gov) - Feb 20, 2015
P1, N=72, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | N=700 --> 360 Not yet recruiting --> Recruiting
- ||||||| praziquantel / Generic mfg.
Trial completion: Safety and Efficacy of Mirazid for Schistosomiasis Treatment (clinicaltrials.gov) - Feb 20, 2015
P3, N=200, Completed, Sponsor: Pharco Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Completed
- Trial completion, Enrollment change: TB036: Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA85A in BCG-vaccinated African Adolescents (clinicaltrials.gov) - Jan 30, 2015
P2, N=36, Completed, Sponsor: University of Oxford
Recruiting --> Completed Recruiting --> Completed | N=90 --> 36
- Sm-TSP-2/Alhydrogel vaccine / Baylor College of Medicine, National Institutes of Health
New P1 trial: A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel (clinicaltrials.gov) - Jan 15, 2015
P1, N=72, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- praziquantel / Generic mfg.
Trial completion: Schistosoma Mansoni Morbidity in Children Aged 1-5 Years (clinicaltrials.gov) - Sep 19, 2014
P2, N=800, Completed, Sponsor: Makerere University
Recruiting --> Completed | N=90 --> 36 Active, not recruiting --> Completed
- Enrollment open, Trial initiation date: NIDIAGDigest: Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders (clinicaltrials.gov) - Aug 6, 2014
P=N/A, N=4000, Recruiting, Sponsor: Swiss Tropical & Public Health Institute
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Apr 2014 --> Jul 2014
- | New P2 trial: TB036: Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA85A in BCG-vaccinated African Adolescents (clinicaltrials.gov) - Jul 1, 2014
P2, N=90, Recruiting, Sponsor: University of Oxford
- ||| praziquantel / Generic mfg.
Clinical: Arachidonic Acid Treatment Against Schistosomiasis Infection in Children (clinicaltrials.gov) - May 20, 2014
P=N/A, N=335, Completed, Sponsor: DSM Nutritional Products, Inc.
- Clinical: NIDIAGDigest: Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders (clinicaltrials.gov) - Apr 3, 2014
P=N/A, N=4000, Not yet recruiting, Sponsor: Swiss Tropical & Public Health Institute
- praziquantel / Generic mfg.
Enrollment closed: Schistosoma Mansoni Morbidity in Children Aged 1-5 Years (clinicaltrials.gov) - Mar 24, 2014
P2, N=800, Active, not recruiting, Sponsor: Makerere University
Not yet recruiting --> Recruiting | Initiation date: Apr 2014 --> Jul 2014 Recruiting --> Active, not recruiting
- Enrollment closed: Health Benefits of Repeated Treatment in Pediatric Schistosomiasis (clinicaltrials.gov) - Mar 6, 2014
P=N/A, N=700, Active, not recruiting, Sponsor: University of Edinburgh
Recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting
- | sulfadoxine/pyrimethamine / Generic mfg.
Enrollment change: PIP-IPT: Impact IPT With Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine in Schoolchildren (clinicaltrials.gov) - Feb 2, 2014
P3, N=616, Completed, Sponsor: Universiteit Antwerpen
Not yet recruiting --> Active, not recruiting N=1300 --> 616
- | sulfadoxine/pyrimethamine / Generic mfg.
Trial completion: PIP-IPT: Impact IPT With Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine in Schoolchildren (clinicaltrials.gov) - Feb 2, 2014
P3, N=616, Completed, Sponsor: Universiteit Antwerpen
N=1300 --> 616 Active, not recruiting --> Completed
- praziquantel / Generic mfg.
Trial completion: Praziquantel-Pharmacokinetic Study (clinicaltrials.gov) - Sep 25, 2013
P1, N=47, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Recruiting --> Completed
- Trial completion, Surgery: Treatment Schistosomal Portal Hypertension: Efficacy of Endoscopy or Surgery (clinicaltrials.gov) - Aug 25, 2013
P=N/A, N=54, Completed, Sponsor: Universidade Estadual de Ci
Recruiting --> Completed Not yet recruiting --> Completed
- praziquantel / Generic mfg.
Trial completion: S. Japonicum and Pregnancy Outcomes (clinicaltrials.gov) - Jul 24, 2013
P2, N=370, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Completed Active, not recruiting --> Completed
- | praziquantel / Generic mfg.
New P2 trial: Schistosoma Mansoni Morbidity in Children Aged 1-5 Years (clinicaltrials.gov) - Jul 15, 2013
P2, N=800, Active, not recruiting, Sponsor: Makerere University
- mefloquine / Generic mfg.
Enrollment change: Activity of Mefloquine Against Urinary Schistosomiasis (clinicaltrials.gov) - Jan 22, 2013
P2, N=65, Completed, Sponsor: Albert Schweitzer Hospital
Active, not recruiting --> Completed N=50 --> 65
- mefloquine / Generic mfg.
Trial completion: Activity of Mefloquine Against Urinary Schistosomiasis (clinicaltrials.gov) - Jan 22, 2013
P2, N=65, Completed, Sponsor: Albert Schweitzer Hospital
N=50 --> 65 Recruiting --> Completed
- ||||||| praziquantel / Generic mfg.
Trial completion: Schistosoma Haematobium Infections and Praziquantel (clinicaltrials.gov) - Jan 15, 2013
P3, N=520, Completed, Sponsor: University of Khartoum
Recruiting --> Completed Recruiting --> Completed
- || sulfadoxine/pyrimethamine / Generic mfg.
New P3 trial: PIP-IPT: Impact IPT With Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine in Schoolchildren (clinicaltrials.gov) - Nov 5, 2012
P3, N=616, Completed, Sponsor: Universiteit Antwerpen
- Trial initiation date: Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis (clinicaltrials.gov) - Mar 21, 2012
P1, N=20, Active, not recruiting, Sponsor: Oswaldo Cruz Foundation
Recruiting --> Completed Initiation date: Jul 2010 --> Mar 2011
- Enrollment closed: Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis (clinicaltrials.gov) - Mar 21, 2012
P1, N=20, Active, not recruiting, Sponsor: Oswaldo Cruz Foundation
Initiation date: Jul 2010 --> Mar 2011 Not yet recruiting --> Active, not recruiting
- |||||||||| praziquantel / Generic mfg.
New P3 trial: Schistosoma Haematobium Infections and Praziquantel (clinicaltrials.gov) - Mar 18, 2012
P3, N=520, Completed, Sponsor: University of Khartoum
- Clinical: Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal (clinicaltrials.gov) - Mar 11, 2012
P=N/A, N=99, Completed, Sponsor: Biomedical Research Center EPLS
- |||||||||| praziquantel / Generic mfg.
New P3 trial: Safety and Efficacy of Mirazid for Schistosomiasis Treatment (clinicaltrials.gov) - Feb 5, 2012
P3, N=200, Recruiting, Sponsor: Pharco Pharmaceuticals
- New P1 trial: Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis (clinicaltrials.gov) - Jan 8, 2012
P1, N=24, Completed, Sponsor: University Hospital, Lille